Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,856 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Omalizumab for the Treatment of Multiple Food Allergies.
Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM, Leung DYM, Vickery BP, Bird JA, Spergel JM, Iqbal A, Olsson J, Ligueros-Saylan M, Uddin A, Calatroni A, Huckabee CM, Rogers NH, Yovetich N, Dantzer J, Mudd K, Wang J, Groetch M, Pyle D, Keet CA, Kulis M, Sindher SB, Long A, Scurlock AM, Lanser BJ, Lee T, Parrish C, Brown-Whitehorn T, Spergel AKR, Veri M, Hamrah SD, Brittain E, Poyser J, Wheatley LM, Chinthrajah RS. Wood RA, et al. Among authors: long a. N Engl J Med. 2024 Mar 7;390(10):889-899. doi: 10.1056/NEJMoa2312382. Epub 2024 Feb 25. N Engl J Med. 2024. PMID: 38407394 Clinical Trial.
Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH).
Wood RA, Chinthrajah RS, Rudman Spergel AK, Babineau DC, Sicherer SH, Kim EH, Shreffler WG, Jones SM, Leung DYM, Vickery BP, Bird JA, Spergel JM, Kulis M, Iqbal A, Kaufman D, Umetsu DT, Ligueros-Saylan M, Uddin A, Fogel RB, Lussier S, Mudd K, Poyser J, MacPhee M, Veri M, Davidson W, Hamrah S, Long A, Togias A; OUtMATCH study team. Wood RA, et al. Among authors: long a. J Allergy Clin Immunol Glob. 2022 Jul 21;1(4):225-232. doi: 10.1016/j.jacig.2022.05.006. eCollection 2022 Nov. J Allergy Clin Immunol Glob. 2022. PMID: 37779534 Free PMC article.
Eliciting Dose and Safety Outcomes From a Large Dataset of Standardized Multiple Food Challenges.
Purington N, Chinthrajah RS, Long A, Sindher S, Andorf S, O'Laughlin K, Woch MA, Scheiber A, Assa'ad A, Pongracic J, Spergel JM, Tam J, Tilles S, Wang J, Galli SJ, Desai M, Nadeau KC. Purington N, et al. Among authors: long a. Front Immunol. 2018 Sep 21;9:2057. doi: 10.3389/fimmu.2018.02057. eCollection 2018. Front Immunol. 2018. PMID: 30298065 Free PMC article. Clinical Trial.
Phase 2, randomized multi oral immunotherapy with omalizumab 'real life' study.
Sindher SB, Kumar D, Cao S, Purington N, Long A, Sampath V, Zedeck SS, Woch MA, Garcia-Lloret M, Chinthrajah RS. Sindher SB, et al. Among authors: long a. Allergy. 2022 Jun;77(6):1873-1884. doi: 10.1111/all.15217. Epub 2022 Jan 24. Allergy. 2022. PMID: 35014049 Clinical Trial.
METHODS: Participants aged 2-25 years with multi-food allergies were pretreated with fixed-dose omalizumab (150 mg, 3 doses, every 4 weeks), and randomized 1:1 to receive mOIT to a total maintenance dose of either 300 or 1200 mg total protein, (total dose includes at least …
METHODS: Participants aged 2-25 years with multi-food allergies were pretreated with fixed-dose omalizumab (150 mg, 3 doses, every 4 weeks), …
Transitioning from epicutaneous to oral peanut immunotherapy.
Wong L, Kost L, Anderson B, Long A, Sindher SB, Chinthrajah RS, Collins WJ. Wong L, et al. Among authors: long a. Front Allergy. 2023 Feb 6;4:1089308. doi: 10.3389/falgy.2023.1089308. eCollection 2023. Front Allergy. 2023. PMID: 36814725 Free PMC article.
Treatment of food allergy: Oral immunotherapy, biologics, and beyond.
Sindher SB, Hillier C, Anderson B, Long A, Chinthrajah RS. Sindher SB, et al. Among authors: long a. Ann Allergy Asthma Immunol. 2023 Jul;131(1):29-36. doi: 10.1016/j.anai.2023.04.023. Epub 2023 Apr 25. Ann Allergy Asthma Immunol. 2023. PMID: 37100276 Review.
The prevalence of food allergy (FA) has been increasing globally and comes with a heavy burden not just economically, but also on quality of life. Although oral immunotherapy (OIT) is effective at inducing desensitization to food allergens, it has several limitations that …
The prevalence of food allergy (FA) has been increasing globally and comes with a heavy burden not just economically, but also on qua …
Analysis of a Large Standardized Food Challenge Data Set to Determine Predictors of Positive Outcome Across Multiple Allergens.
Sindher S, Long AJ, Purington N, Chollet M, Slatkin S, Andorf S, Tupa D, Kumar D, Woch MA, O'Laughlin KL, Assaad A, Pongracic J, Spergel JM, Tam J, Tilles S, Wang J, Galli SJ, Nadeau KC, Chinthrajah RS. Sindher S, et al. Among authors: long aj. Front Immunol. 2018 Nov 27;9:2689. doi: 10.3389/fimmu.2018.02689. eCollection 2018. Front Immunol. 2018. PMID: 30538699 Free PMC article.
New Developments in Non-allergen-specific Therapy for the Treatment of Food Allergy.
Long A, Borro M, Sampath V, Chinthrajah RS. Long A, et al. Curr Allergy Asthma Rep. 2020 Jan 16;20(1):3. doi: 10.1007/s11882-020-0897-8. Curr Allergy Asthma Rep. 2020. PMID: 31950290 Review.
At the current time, there are no approved treatments for food allergy. Major limitations of immunotherapy are long treatment periods (months or years), frequent clinic visits, high costs, increased risk of adverse events during treatment, and lack of durability of desensi …
At the current time, there are no approved treatments for food allergy. Major limitations of immunotherapy are long treatment periods …
1,856 results